NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date (Ascending) | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
70860-0200-17 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 24, 2017 | Nov. 30, 2024 | In Use |
70860-0215-67 | 70860-0215 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec. 15, 2021 | Nov. 30, 2024 | In Use |
49884-0290-01 | 49884-0290 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Aug. 8, 1988 | Dec. 31, 2024 | In Use | |
49884-0290-05 | 49884-0290 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Aug. 8, 1988 | Dec. 31, 2024 | In Use | |
60429-0265-01 | 60429-0265 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Oct. 26, 2012 | Dec. 31, 2024 | In Use |
60429-0433-01 | 60429-0433 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Sept. 4, 2015 | Dec. 31, 2024 | In Use | |
70860-0200-05 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 24, 2017 | Dec. 31, 2024 | In Use |
70860-0200-50 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 24, 2017 | Dec. 31, 2024 | In Use |
70860-0219-20 | 70860-0219 | decitabine | Decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug. 15, 2021 | Dec. 31, 2024 | In Use |
71288-0165-53 | 71288-0165 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan. 10, 2023 | Jan. 2, 2025 | In Use |
70934-0634-84 | 70934-0634 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 13, 2021 | Jan. 31, 2025 | In Use |
00955-1727-20 | 00955-1727 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | July 7, 2014 | Jan. 31, 2025 | In Use |
60505-6166-00 | 60505-6166 | clofarabine | Clofarabine | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan. 1, 2018 | Jan. 31, 2025 | In Use |
70934-0264-10 | 70934-0264 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 9, 2020 | Jan. 31, 2025 | In Use |
70934-0264-12 | 70934-0264 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 7, 2019 | Jan. 31, 2025 | In Use |
00781-3253-94 | 00781-3253 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Sept. 16, 2013 | Feb. 28, 2025 | In Use |
70934-0809-83 | 70934-0809 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 22, 2021 | Feb. 28, 2025 | In Use |
70934-0809-87 | 70934-0809 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 22, 2021 | Feb. 28, 2025 | In Use |
70934-0809-95 | 70934-0809 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 8, 2020 | Feb. 28, 2025 | In Use |
57962-0560-28 | 57962-0560 | Ibrutinib | IMBRUVICA | 560.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Feb. 16, 2018 | Feb. 28, 2025 | In Use |
70934-0318-10 | 70934-0318 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 4, 2019 | Feb. 28, 2025 | In Use |
70860-0785-05 | 70860-0785 | Palonosetron hydrochloride | Palonosetron Hydrochloride | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Oct. 1, 2022 | Feb. 28, 2025 | In Use |
60687-0455-21 | 60687-0455 | Abiraterone | Abiraterone Acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Nov. 1, 2019 | Feb. 28, 2025 | In Use |
16714-0001-01 | 16714-0001 | Doxorubicin hydrochloride | Doxorubicin hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | March 22, 2021 | March 1, 2025 | In Use |
76388-0880-25 | 76388-0880 | Thioguanine | Tabloid | 40.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | March 12, 2013 | March 31, 2025 | In Use |
Found 10,000 results in 6 milliseconds — Export these results